JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Cogent Biosciences Inc

Geschlossen

35.83 0.42

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

35.36

Max

36.39

Schlüsselkennzahlen

By Trading Economics

Einkommen

-22M

-102M

Angestellte

258

EBITDA

-30M

-109M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+42.54% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

645M

6.3B

Vorheriger Eröffnungskurs

35.41

Vorheriger Schlusskurs

35.83

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Apr. 2026, 23:53 UTC

Ergebnisse

Naver Posts Weaker First-Quarter Earnings

29. Apr. 2026, 23:41 UTC

Heiße Aktien

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29. Apr. 2026, 23:55 UTC

Ergebnisse

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29. Apr. 2026, 23:54 UTC

Ergebnisse

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29. Apr. 2026, 23:52 UTC

Ergebnisse

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29. Apr. 2026, 23:51 UTC

Ergebnisse

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29. Apr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29. Apr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29. Apr. 2026, 23:22 UTC

Ergebnisse

China Longyuan 1Q Net CNY1.70B, Down 14%

29. Apr. 2026, 23:22 UTC

Ergebnisse

China Longyuan: Power Generation Down 2.9% as of End-March

29. Apr. 2026, 23:20 UTC

Ergebnisse

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29. Apr. 2026, 23:20 UTC

Ergebnisse

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Loss Narrows>000002.SZ

29. Apr. 2026, 23:18 UTC

Ergebnisse

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29. Apr. 2026, 23:17 UTC

Ergebnisse

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29. Apr. 2026, 23:15 UTC

Ergebnisse

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29. Apr. 2026, 23:15 UTC

Ergebnisse

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29. Apr. 2026, 23:13 UTC

Ergebnisse

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29. Apr. 2026, 23:12 UTC

Ergebnisse

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29. Apr. 2026, 23:11 UTC

Ergebnisse

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29. Apr. 2026, 23:11 UTC

Ergebnisse

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29. Apr. 2026, 23:04 UTC

Ergebnisse

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29. Apr. 2026, 23:04 UTC

Ergebnisse

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

42.54% Vorteil

12-Monats-Prognose

Durchschnitt 51.8 USD  42.54%

Hoch 64 USD

Tief 35 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

9

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Strong Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
help-icon Live chat